Total glucosides of paeony for the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials

• Published in: Phytomedicine (Stuttgart) 2019-09, Vol.62 (C), p.152940, Article 152940
• Main Authors: Zheng, Qi, Jiang, WenCheng, Sun, XiaoYing, Ma, Tian, Xu, WenBin, Shen, Fang, Li, HongJin, Xie, ShaoQiong, Li, Bin, Li, Xin
• Format: Article
• Language: English
• Subjects: Adverse reactions; Dermatologic Agents - adverse effects; Dermatologic Agents - therapeutic use; Glucosides - adverse effects; Glucosides - therapeutic use; Glycosides - therapeutic use; Humans; Monoterpenes - adverse effects; Monoterpenes - therapeutic use; Paeonia - chemistry; Psoriasis; Psoriasis - drug therapy; Randomized controlled trials; Randomized Controlled Trials as Topic; Total glucosides of paeony
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2019.152940

Psoriasis is a common chronic relapsing immune-mediated inflammatory disease, the prevalence of which has increased in recent years. At present, there are many treatment methods available for the condition, but the curative effect is unsatisfactory. This study aimed to evaluate the efficacy, adverse reactions, and recurrence rates of using paeoniflorin capsules for psoriasis treatment. systematic review and meta-analysis. Randomized controlled trials comparing total glycosides of paeony (TGP) with other treatments for patients with psoriasis were retrieved by searching EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials electronic databases. Cochrane bias risk tool was used to evaluate the quality of randomized controlled trial (RCT) methodology. The primary outcome measure is the effective number. Secondary outcomes included psoriasis area and severity index (PASI), adverse reactions, recurrence, and inflammatory biomarkers. In all, 30 RCTs with 2,802 participants were included in this meta-analysis. The studies were generally of low methodological quality. Although there was no statistically significant difference between the use of TGP capsule alone and other monotherapies in the treatment of psoriasis (RR: 0.93; 95% CI: 0.76–1.15; p = 0.50), the addition of TGP to other therapies had an advantage over monotherapy with regard to the effective number (RR: 1.31; 95% CI: 1.26–1.37; p < 0.00001), PASI (RR: −3.40; 95% CI: −4.22,−2.57; p < 0.00001), adverse reactions, recurrence rate (RR: 0.42; 95% CI: 0.24–0.74; p = 0.002), and inflammatory inhibition (RR:−12.54; 95% CI: −18.50, −6.59; p < 0.0001). TGP can be used to treat psoriasis with reduced adverse reactions and recurrence rates. However, the mechanism of TGP in psoriasis treatment requires to be evaluated further in high-quality, large-sample, and rigorous clinical studies.